• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Dexcom inks 5-year diabetes research pact with U of Virginia

Dexcom inks 5-year diabetes research pact with U of Virginia

September 24, 2020 By Sean Whooley

Dexcom updated logoDexcom (NSDQ:DXCM) announced today that it signed a five-year collaboration agreement with the University of Virginia for CGM research.

The partnership will focus on advancing Dexcom’s automated insulin delivery technology and exploring the use of continuous glucose monitoring (CGM) tools outside the Type 1 diabetes market, which includes inpatient hospital use, Type 2 diabetes and gestational diabetes, according to a news release.

San Diego-based Dexcom acquired its automated insulin delivery technology from Virginia-based startup TypeZero Technologies in 2018 and established a Charlottesville, Va., office, offering opportunities to collaborate with the University of Virginia, which is located in Charlottesville.

Dexcom’s next-generation closed-loop algorithms will be refined and piloted in a series of clinical trials as part of the collaboration, while the company’s Charlottesville team will expand in conjunction with the research collaboration, which will be spearheaded by the university’s Center for Diabetes Technology and will engage the School of Engineering, the School of Data Science and the School of Medicine at the university.

“Dexcom is committed to bringing innovative continuous glucose monitoring-based solutions to empower customers and clinicians toward greater health outcomes,” Dexcom chairman, president & CEO Kevin Sayer said in the release. “We are investing heavily in research and development efforts that explore new diagnostic tools and treatments. By partnering with a top-tier research institution like the University of Virginia, we hope to bring better CGM solutions to patients much faster than we could alone.”

Dexcom and the University of Virginia intend to commence their partnership in late 2020, with the company providing research funding to the university over a five-year period.

“The University of Virginia has become one of the world’s leading research institutes for diabetes technology,” University of Virginia president Jim Ryan said. “This expanded commitment from Dexcom ensures that research conducted on Grounds has a clear path to enrich and improve the lives of patients and caregivers managing this complicated and all too common disease.”

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Patient Monitoring, Research & Development Tagged With: Dexcom, University of Virginia

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy